

5477, 787-759-9445, ext. 204, FAX 787-756-7670. The fee covers refreshments, organization and site costs, and materials. Space is limited; therefore interested parties are encouraged to register early. Please arrive early to ensure prompt registration.

If you need special accommodations due to a disability, please inform Jose P. Rodriguez (address above) at least 7 days in advance of the workshop.

*Contact:* H. Gordon Cox, Supervisory Investigator, FDA San Juan District Office, 466 Fernandez Juncos Ave., San Juan, PR 787-729-6801.

**SUPPLEMENTARY INFORMATION:** In the fall of 1999, the FDA field offices began using QSIT nationwide as the primary tool for medical device good manufacturing practice/quality system (GMP/QS) inspections. QSIT was developed using a collaborative effort with stakeholders, and it was tested in three districts.

The workshop helps to implement the objectives of section 406 of the FDA Modernization Act (21 U.S.C. 393) and the FDA Plan for Statutory Compliance, which includes working more closely with stakeholders and ensuring access to needed scientific and technical expertise.

The workshop is also consistent with the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121) by providing outreach activities directed to small businesses.

Dated: February 23, 2000.

**William K. Hubbard,**

*Senior Associate Commissioner for Policy, Planning, and Legislation.*

[FR Doc. 00-4662 Filed 2-23-00; 4:20 pm]

**BILLING CODE 4160-01-F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee:* Vaccines and Related Biological Products Advisory Committee.

*General Function of the Committee:* To provide advice and

recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on March 9, 2000, 8 a.m. to 6 p.m., and on March 10, 2000, 8 a.m. to 3 p.m.

*Location:* Holiday Inn, Kennedy Ballroom, 8777 Georgia Ave., Silver Spring, MD.

*Contact Person:* Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12391.

Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On March 9, 2000, the committee will discuss the safety and efficacy of a combination vaccine from SmithKline Beecham for the prevention of Diphtheria/Tetanus, Pertussis, Polio, and Hepatitis B. On March 10, 2000, the committee will: (1) Complete recommendations pertaining to the influenza virus vaccine formulations for the 2000 to 2001 season, (2) hear a short briefing on the Vaccine Safety Action Plan, and (3) be updated on the status of vaccines for the prevention of rotavirus disease.

*Procedure:* On March 9, 2000, from 9:15 a.m. to 6 p.m., and on March 10, 2000, from 8 a.m. to 3 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 3, 2000. Oral presentations from the public will be scheduled between approximately 9:30 a.m. and 9:45 a.m. and between approximately 4 p.m. and 4:15 p.m. on March 9, 2000. Oral presentations from the public will be heard on March 10, 2000, between approximately 10:20 a.m. and 10:30 a.m., between approximately 12:30 p.m. and 12:45 p.m., and between approximately 2:45 p.m. and 3 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 1, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations:* On March 9, 2000, from 8 a.m. to 9:15 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information. (5 U.S.C. 552b(c)(4)). These portions of the

meeting will be closed to discuss issues relating to pending or proposed investigational new drug applications.

FDA regrets that it was unable to publish this notice 15 days prior to the March 9 and 10, 2000, Vaccines and Related Biological Products Advisory Committee meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Vaccines and Related Biological Products Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 16, 2000.

**Linda A. Suydam,**

*Senior Associate Commissioner.*

[FR Doc. 00-4589 Filed 2-23-00; 3:44 pm]

**BILLING CODE 4160-01-F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on (301) 443-1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

#### Proposed Project: Voluntary Partner Surveys To Implement Executive Order 12862 in the Health Resources and Services Administration—(OMB 0915-0212)—Extension

In response to Executive Order 12862, the Health Resources and Services Administration (HRSA) is proposing to conduct voluntary customer surveys of its "partners" to assess strengths and weaknesses in program services. A generic approval is being requested from OMB to conduct the partner surveys. HRSA partners are typically State or local governments, health care facilities,

health care consortia, health care providers, and researchers.

Partner surveys to be conducted by HRSA might include, for example, mail or telephone surveys of grantees to determine satisfaction with a technical assistance contractor, or in-class evaluation forms completed by providers who receive training from HRSA grantees to measure satisfaction

with the training experience. Results of these surveys will be used to plan and redirect resources and efforts as needed to improve service. Focus groups may also be used to gain partner input into the design of mail and telephone surveys. Focus groups in-class evaluation forms, mail surveys, and telephone surveys are expected to be the preferred methodologies.

A generic approval will permit HRSA to conduct a limited number of partner surveys without a full-scale OMB review of each survey. If generic approval is granted, information on each individual partner survey will not be published in the **Federal Register**.

The estimated response burden is as follows:

Type of survey	Number of respondents	Responses per respondent	Hours per response	Total hour burden
In-class evaluations .....	40,000	1	.05	2,000
Mail/Telephone surveys .....	12,000	1	.25	3,000
Focus groups .....	50	1	1.5	75
<b>Total .....</b>	<b>52,050</b>	<b>.....</b>	<b>.....</b>	<b>5,075</b>

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Wendy A. Taylor, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: February 16, 2000.

**Jane Harrison,**

*Director, Division of Policy Review and Coordination.*

[FR Doc. 00-4533 Filed 2-25-00; 8:45 am]

**BILLING CODE 4160-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Health Resources and Services Administration**

**AGENCY:** Health Resources and Services Administration.

**ACTION:** Notice; correction.

**SUMMARY:** In the **Federal Register** issue of Thursday, August 18, 1999, make the following correction:

**Correction**

In the **Federal Register** issue of Wednesday, August 18, 1999, in FR Doc. 99-21257, on page 45027, the grant category beginning in the first column under the heading "Health and Welfare Technical Advisory Group (CFDA# 93.110AI)" is withdrawn from

competition due to consideration of alternative mechanisms to fund proposed activities.

Dated: February 18, 2000.

**James J. Corrigan,**

*Associate Administrator for Management and Program Support.*

[FR Doc. 00-4534 Filed 2-25-00; 8:45 am]

**BILLING CODE 4160-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Submission for OMB Review; Comment Request; NIH Intramural Research Training Award, Program Application**

**SUMMARY:** Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the Office of the Director, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the **Federal Register** on Thursday, October 28, 1999, page 58071 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not

conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

**Proposed Collection**

*Title:* NIH Intramural Research Training Award, Program Application; *Type of Information Collection Request:* Revision of OMB No. 0925-0299; 4/30/2000; *Need and Use of Information Collection:* The proposed information collection activity is for the purpose of collecting data related to the availability of Training Fellowships under the NIH Intramural Research Training Award Program. This information must be submitted in order to receive due consideration for an award and will be used to determine the eligibility and quality of potential awardees. *Frequency of Response:* On occasion. *Affected Public:* Individuals seeking Intramural Training award opportunities. *Type of Respondents:* Postdoctoral, Predoctoral, Post-baccalaureate, Technical, and Student IRTA applicants.

*Estimated Number of Respondents:* 15,779. *Estimated Number of Responses Per Respondent:* 1. *Average Burden Hours Requested:* .53 *Estimated Total Annual Burden Hours Requested:* 8,422.

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Type of respondent	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Postdoctoral IRTA .....	1,089	1	1	1,089
Predoctoral .....	6	1	1	6
Postbaccalaureate .....	290	1	1	290
Technical IRTA .....	27	1	1	27